EUVIMEDEUVIMED entdecken
Crossref

Approach to ensure quality of pharmaceutical care for cognitive impairment – integrative utilization of Ginkgo biloba L. leaf extract

A J Scholl, A Drebka, R Mösges, S B Frenzel, B E Bachmeier

Planta Medica · 01.03.2026 · 92 (03) · 410

DOI: 10.1055/s-0045-1815433 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Planta Medica, erschienen am 01.03.2026. Verfasst von A J Scholl und 4 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The prevalence of cognitive impairment like dementia is rising, making prevention and intervention increasingly important. According to the EMA/HMPC, refined and quantified Ginkgo biloba L. leaf extract is proven effective and safe in treatment [ 1 ]. To ensure the quality of pharmaceutical care in everyday practice, real-world data (RWD) are necessary to evaluate utilization, effectiveness and tolerability. Therefore, we analyzed patient-reported outcomes (PROs) from 191 patients with cognitive impairment regarding the utilization of Ginkgo biloba L. leaf extract (GBE), taken from the pharmaco-epidemiological database PhytoVIS. Our results indicate that patients used GBE to treat chronic (41%) or acute (20%) symptoms, but also for prevention (39%). Patients took GBE daily (>97%) and for longer periods (>30 days: 86%). Older patients used GBE significantly longer compared to younger patients ( p =0.002, r =0.228). Daily doses were predominantly 120 mg (37%) and 240 mg (35%) – interestingly, men chose significantly higher doses than women ( p =0.021, r =0.168). The vast majority (>90%) perceived a therapeutic benefit. Longer use of GBE (>30 days) was significantly associated with higher perceived effectiveness compared to shorter use ( p =0.005, r =0.207). Although men took higher doses, they did not experience greater benefits. Self-reported tolerability was high, with 89.0% not reporting adverse drug events (AEs). Our findings suggest a favorable benefit-risk ratio of GBE for treatment and prevention of cognitive impairment, especially for long-term use. Regarding the quality of pharmaceutical care, it must be clarified how certain factors such as dosage, duration or frequency of application influence effectiveness and tolerability in the real world. Publication History Article published online: 05 March 2026 © 2026. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

Zitieren

APA

Scholl, A. J., Drebka, A., Mösges, R., Frenzel, S. B., & Bachmeier, B. E. (2026). Approach to ensure quality of pharmaceutical care for cognitive impairment – integrative utilization of Ginkgo biloba L. leaf extract. Planta Medica, 92(03), 410. https://doi.org/10.1055/s-0045-1815433

Vancouver

Scholl AJ, Drebka A, Mösges R, Frenzel SB, Bachmeier BE. Approach to ensure quality of pharmaceutical care for cognitive impairment – integrative utilization of Ginkgo biloba L. leaf extract. Planta Medica. 2026;92(03):410. doi:10.1055/s-0045-1815433

BibTeX
@article{Scholl2026,
  author = {Scholl, A J and Drebka, A and Mösges, R and Frenzel, S B and Bachmeier, B E},
  title = {Approach to ensure quality of pharmaceutical care for cognitive impairment – integrative utilization of Ginkgo biloba L. leaf extract},
  journal = {Planta Medica},
  year = {2026},
  volume = {92},
  number = {03},
  pages = {410},
  doi = {10.1055/s-0045-1815433}
}
Kostenlos starten →